In the third and final part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko talks about the importance of real-world data in bolstering biosimilars, as well as outlining the firm’s future pipeline.
As CEO of the Samsung Bioepis joint venture between Samsung BioLogics and Biogen, Christopher Hansung Ko oversees a major player in the global biosimilars market.
In the first two parts of this exclusive interview, Ko discussed Samsung Bioepis’ interests in the US (Also see "
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
